Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.62 |
| ▸ | CTSS | P25774 | 7/20 | 0.62 |
| ▸ | CTSB | P07858 | 7/20 | 0.62 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14491527 | 0.78 | ERCC1 (0.71) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL14067363 | 0.73 | SMN1; SMN2 (0.68) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL9829124 | 0.70 | SMN1; SMN2 (0.68) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL2857030 | 0.69 | ERCC1 (0.70) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL14491548 | 0.69 | ERCC1 (0.50) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL5346968 | 0.69 | ERCC1 (0.75) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL20060916 | 0.68 | SMN1; SMN2 (0.65) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL14491532 | 0.68 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL7979818 | 0.68 | HDAC4 (0.72) | SMN1; SMN2HTTERCC1ERCC4LMNA | |
| SCHEMBL2861856 | 0.68 | ERCC1 (0.68) | SMN1; SMN2HTTERCC1ERCC4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | CTSL 15/4885CTSS 27/4885CTSB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.